In a small study, single-dose instillation of mitomycin C immediately following therapeutic ureteroscopy for upper tract urothelial carcinoma was associated with an 87% decreased risk of urothelial recurrence.
Patients who receive epidural anesthesia at the time of radical cystectomy, compared with those who do not, are more likely to have a myocardial infarction and to be readmitted to a hospital within 30 days following surgery.
Adjuvant platinum-based chemotherapy for upper tract urothelial carcinoma within 90-days of nephroureterectomy improves disease-free and metastasis-free survival compared with surveillance, a study found.
Larger tumor size and more advanced tumor stage are associated with an increased risk of intravesical recurrence among patients undergoing radical nephroureterectomy for in upper tract urothelial carcinoma.
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
In a study, patients with upper tract urothelial carcinoma and pathologic vascular invasion who received adjuvant chemotherapy had significantly longer overall survival than those who did not receive adjuvant chemotherapy.
Many individual metabolite changes are often common among cancers and not specific to RCC, making the identification of diagnostic or prognostic biomarkers difficult.
In a single-center study of 177 patients with metastatic renal cell carcinoma who received at least a single dose of an immune checkpoint inhibitor, the median time to next treatment was 8.9 months and median overall survival time was 26.7 months.
